tHEORetically Speaking
Menu Close
  • Home
  • Guest Authors
  • About Us
  • HealthEconomics.Com
  • HE Jobs Portal

Steve Pearson

0

Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.

Posted on July 30, 2015 by Swarali Tadwalkar

Hardly a day goes by without a new article being published in the mainstream press or a medical journal discussing drug pricing.  The cost of drugs is a hot potato topic at medical meetings, pharma conference rooms, government hearings, and… Continue Reading →

cost-effectiveness, health economic models, health outcome models, modeling, Pharmaceutical Pricing, simulation, Value Access benchmark reports, comparative effectiveness, cost-effectiveness analysis, Dan Ollendorf, Emerging Therapy Assessment and Pricing, Evidence-based medicine, ICER, Institute for Clinical and Economic Review, patti peeples, pharmaceutical industry, Steve Pearson

About the HealthEconomics.Com Blog:

Insights, observations, executive interviews, critical analysis, and new research for health economics, outcomes research, real-world evidence, and market access community. We welcome guest bloggers.

Check your inbox or spam folder to confirm your subscription.

Recent Posts

  • Between Two Scientists: Data Linkage – Like Making a Fine, Blended Wine from Varietal Data Sources
  • The Sooner, the Better: Detecting and Decoding Alzheimer’s with Real-World Data
  • Ongoing Medicare Privatization Will Hurt Pharma As Much As the IRA
  • Leveraging Real-World Data for Precision Obesity Treatment

HealthEconomics.Com Twitter Feed

www_healthecon Follow

@ ·
now

Reply on Twitter Retweet on Twitter Like on Twitter Twitter
Load More...

Archives

Visit our website, HealthEconomics.Com, top ranked by Google for news, jobs and resources in healthcare value, market access and more. Read our privacy policy here.
© 2023 tHEORetically Speaking. All rights reserved.
Hiero by aThemes